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Abstract
The receptor-binding domain of Plasmodium vivax Duffy binding protein, region II (PvRII), is an
attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and
immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII
with a C-terminal 6-histidine tag was expressed in E. coli, recovered from inclusion bodies, refolded
into its functional conformation, purified to homogeneity and formulated with three adjuvants,
namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use
in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly
immunogenic. The overall magnitude of the antibody response was significantly higher for both
Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there
was a significant correlation between antibody recognition titers by ELISA and binding inhibition
titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-γ recall responses
that were identified using ex vivo ELISPOT assays. These results provide support for further clinical
development of a vaccine for P. vivax malaria based on recombinant PvRII.
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1. Introduction
The annual number of clinical cases of malaria is estimated to be over 500 million with the
number of fatal malaria cases being greater than one million [1]. These numbers place malaria
at the top of the list of transmissible diseases with significant global health impact. The
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epidemiology of malaria is characterized by increased prevalence of insecticide-resistant
vectors and drug-resistant parasites resulting in the failure of vector and parasite control
measures [2]. Plasmodium falciparum and P. vivax are the two species of malaria parasites
that are the primary cause of human malaria. Epidemiological evidence has indicated that
following repeated exposure, clinical immunity to malaria is acquired by residents of endemic
areas suggesting that the development of a malaria vaccine should be feasible [3].
Merozoite proteins that are involved in erythrocyte invasion are important candidates for the
development of vaccines aimed at neutralizing blood-stage growth by modifying the kinetics
of erythrocyte invasion. Extensive research has shown that the invasion of human erythrocytes
by P. vivax and the related simian species P. knowlesi is completely dependent on merozoite
interaction with the Duffy antigen receptor for chemokines (DARC) [4-7]. The P. vivax and
P. knowlesi Duffy binding proteins (PvDBP and PkDBP), which mediate this interaction,
belong to a family of erythrocyte binding proteins (EBP) that also includes the 175 kD P.
falciparum erythrocyte binding antigen (EBA-175) [8]. The binding domains of EBPs reside
in conserved, extracellular, cysteine-rich regions known as region II [9]. Antibodies raised
against region II, the receptor-binding domain of PkDBP, have been shown to block erythrocyte
invasion by P. knowlesi [10]. This result provides support for the development of a vaccine for
P. vivax malaria based on the homologous receptor-binding domain, region II (PvRII), of
PvDBP. It has been demonstrated that naturally acquired antibodies elicited against PvDBP
can block the binding of PvRII to Duffy positive human erythrocytes although the binding
inhibitory activity is poor [11,12]. Interestingly, structural analysis has demonstrated that
clusters of polymorphic amino acid residues in PvRII from P. vivax field isolates lie in regions
that are distant from the binding site [13]. The DARC binding site within PvRII thus does not
appear to be under significant immune pressure. Although high titer binding inhibitory
antibodies against PvRII do not develop upon natural exposure to P. vivax [14], it is possible
to raise high titer binding inhibitory antibodies by immunization with recombinant PvRII
[15]. Importantly, since the polymorphism clusters are distal to the binding site, anti-PvRII,
binding inhibitory antibodies elicited by immunization should be effective against diverse P.
vivax isolates [16].
We have previously described the production of recombinant PvRII in its functional, correctly
folded form [17,18]. Immunization with recombinant PvRII formulated with Freund’s adjuvant
has been shown to provide partial protection to Aotus lemurinus griseimembra monkeys against
P. vivax blood stage challenge [19]. The immunogenicity of recombinant PvRII formulated
with human compatible adjuvants has also been studied in small animals [15]. Of the five
adjuvants tested, namely, Montanide ISA 720, AS02A, MF59, QS21 and Alhydrogel,
formulations made with Montanide ISA 720 and AS02A elicited the highest titer binding
inhibitory antibodies [15]. Recombinant PvRII formulated with Alhydrogel also yielded
antibodies with significant binding inhibitory activity. Based on these observations, we decided
to test the safety and immunogenicity of recombinant PvRII formulated in Montanide ISA 720,
AS02A and Alhydrogel in rhesus monkeys. Safety of these PvRII vaccine formulations was
assessed by characterization of several clinical, haematological and biochemical parameters at
different time points after immunization. The immunogenicity of PvRII in rhesus monkeys
was determined by measuring end point titers for recognition of PvRII by total IgG using
ELISA, measuring 50% binding inhibition titers using in vitro PvRII-DARC binding assays
and by characterizing the prevalence of protein-specific IFN-γ secreting cells by ex vivo
ELISPOT assays. We report that all three adjuvant formulations were found to be safe and
highly immunogenic in rhesus monkeys. All three formulations tested yielded high titer
antibodies with significant binding inhibitory activity. Montanide ISA 720 and AS02A
formulations had higher binding inhibitory activity than the Alhydrogel formulation. These
results provide support for further development of a vaccine for P. vivax malaria based on
PvRII.
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2. Materials and Methods
2.1. Animals
A group of 60 rhesus macaques of Chinese origin from the Yerkes National Primate Research
Center facility were initially included in the study. The monkeys were screened for antibody
reactivity against PvRII by ELISA and to simian malaria parasites by immunofluorescence
using P. cynomolgi-infected red blood cells. From this group, thirty-six healthy, malaria naïve
rhesus macaques were included in the immunization protocol (Table 1). Selected animals were
matched by age, sex and weight, housed in social settings and randomly assigned to six
experimental groups of 5 individuals each that received different vaccine formulations (Groups
1-6) and three control groups of two individuals each that received adjuvant alone (Groups
7-9). The procedures were approved by Emory University’s Institutional Animal Care and Use
Committee.
2.2. Vaccine formulation and immunization schedule
The production and characterization of recombinant PvRII has been described previously
[17,20]. Briefly, a gene coding for PvRII from P. vivax Salvador I strain (aminoacid D194-
T521; GenBank accession number M61095) was cloned as a NcoI-SalI fragment in the E.
coli expression vector pET28a(+) as described [17]. Bacterial transformation for expression
of the recombinant construct was performed using E. coli BL21 (DE3) cells (Novagen,
Madison, WI) and kanamycin selection. Protein expression of the recombinant 6-His tag PvRII
was induced with 1 mM IPTG for 4 hours, purified by metal affinity chromatography under
denaturing conditions, refolded by rapid dilution and purified further to homogeneity by ion
exchange and gel filtration chromatography resulting in a protein of apparent molecular mass
of ~39 kDa. The molecular mass determined by electron spray ionization mass spectrometry
was 39,802 Da. Refolded PvRII was characterized for purity, homogeneity, identity and
functional activity by SDS-PAGE, western blotting, reverse phase chromatography and
erythrocyte binding assays as described previously [17]. Using reverse phase chromatography
refolded PvRII elutes as a single, homogeneous product. The endotoxin content of purified
PvRII was less than 25 EU per 25 μg using standard LAL assay [15,21]. Recombinant PvRII
was formulated with either Alhydrogel [15], Montanide ISA 720 (Seppic, France) or AS02A
Adjuvant System (GlaxoSmithKline Biologicals, Belgium) prior to immunization following
manufacturers’ protocols. The final formulation was adjusted to 0.5 ml containing 50μg or 10
μg of PvRII (see Table 1). Groups 1 and 2 were immunized with 50 μg and 10 μg of PvRII
adsorbed to Alhydrogel, respectively. Groups 3 and 4 received 50 μg and 10 μg of PvRII
emulsified in Montanide ISA 720, respectively. Groups 5 and 6 were immunized with 50 μg
and 10 μg of PvRII formulated in AS02A, respectively. Six control animals were distributed
in three groups (Groups 7 to 9) of two individuals each. Groups 7, 8 and 9 received saline
solution adsorbed to Alhydrogel, Montanide ISA 720 and AS02A, respectively. The
immunizations were given intramuscularly (IM) using the following schedule: priming into
the right quadriceps femoris on day 0, first boost into the right musculus deltoideus on day 60
and the last boost into the left musculus deltoideus on day 150. Immunizations were given
using a tuberculin syringe and a 22 gauge needle. Blood samples were obtained by femoral
phlebotomy at seven time points before and during the study on days 0, 30, 60, 90, 120, 150
and 180. Serum and plasma were separated and either used for clinical chemistry assays
immediately or frozen in aliquots at -80 °C for immunological studies. Peripheral blood
mononuclear cells (PBMC) were isolated by Ficoll-Hypaque density gradients and frozen in
aliquots at -80 °C for use in ELISPOT assays.
2.3. Clinical characterization and safety assays
Animals were observed for general behavior and visible side effects during the entire study by
two veterinary clinicians and their staff. Observations included analysis of skin for warmth,
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erythema and edema/swelling, and for muscle induration or necrosis. The clinical veterinary
staff examining the animals and injection sites was blinded to which vaccine formulation had
been given. At the specified time points, the animals were sedated for bleedings and
examination of the injection sites by the veterinary clinician. The total observation period of
the animals was 240 days. Analysis of hematology and clinical chemistry of the different
animals was performed on days 0, 30, 60, 90, 120, 150 and 180. Hematological analysis
consisted of determination of number of erythrocytes (RBC), leukocytes (WBC), hemoglobin
(HGB), hematocrit (HCT), mean cell volume (MCV) and platelets (PLT). Analysis of clinical
chemistry consisted of glucose, blood urea nitrogen (BUN), creatinine, protein, albumin,
alkaline phosphatase, serum glutamic pyruvic transaminase (SGPT), serum glutamic
oxaloacetic transaminase (SGOT), amylase and creatine phosphokinase (CPK) determinations.
2.4. ELISA
Sera were tested for recognition of PvRII by ELISA using Immulon-2 plates (Dynatech
Laboratories, Chantilly, VA) coated with 1 μg/ml of the recombinant protein. Antigen
specificity was confirmed by testing sera samples with a P. yoelii his-tag recombinant protein
and synthetic peptides containing a (His)5 sequence (VDKLAAALEHHHHH and
HHHHHLESTSLYKKAG). After blocking with 5% bovine serum albumin (BSA), the plates
were incubated with individual sera diluted in PBS with 2.5% BSA for 1 h at 37°C. Bound
antibodies were detected using peroxidase-labeled goat anti-monkey IgG (Kirkegaard & Perry
Laboratories, Gaithersburg, MD) and H2O2/2,2’-azinobis (3-ethylbenzthiazoline-6-sulfonic
acid) (ABTS) as substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD). Optical
densities (OD) were determined using a VERSAmax ELISA reader (Molecular Device
Corporation, Sunnyvale, CA) with a 405 nm filter. The reciprocal end point antibody titers,
defined as the last serum dilution that yielded an OD greater than mean OD plus two standard
deviations (SD) obtained with malaria naïve rhesus macaques at 1:200 dilution was considered
as the endpoint ELISA titer.
2.5 Blocking of binding of PvRII to DARC-Fc by rhesus sera
Inhibition of binding of PvRII to DARC by sera from immunized rhesus macaques was
determined using an ELISA-based binding assay. The N-terminal extracellular region of
DARC was expressed as a fusion to Fc of human IgG (DARC-Fc) in a mammalian cell culture
system as previously described [22]. ELISA plates were coated with 1 μg/ml DARC-Fc using
sodium bicarbonate buffer pH 9.6 and the plates incubated overnight at 4°C. The plates were
then washed three times with PBS pH 7.4 containing 0.05% Tween 20. Plates were then blocked
with 1% skimmed milk in PBS for 2 hours at 37°C. Pooled rhesus sera from groups 1 to 6
collected on days 30, 90, 150 or 180 were used as test sera. Pre-immune sera and adjuvant
alone sera from each group were used as controls. PvRII (0.1μg/ml) was pre-incubated with
pooled sera at final dilutions of 1:10, 1:50, 1:250, 1:1,250 and 1:6,250 for 1 hour at room
temperature prior to addition to DARC-Fc coated plates. Sera from pre-immune and adjuvant
control groups were used at a dilution of 1:10. PvRII (0.1 μg/ml) without sera was used as
positive control for binding to DARC-Fc. PvRII with/without sera was allowed to bind DARC-
Fc coated wells for 1 hour at 37°C. Bound PvRII was then detected with anti-PvRII rabbit
polyclonal sera (1:1,500), followed by mouse anti-rabbit IgG conjugated to horseradish
peroxidase (Sigma Aldrich Corp., St Louis, MO) at a dilution of 1:2,500. Plates were developed
using o-phenelenediamine (Sigma Aldrich Corp., St Louis, MO). Mean OD (A490 nm) values
from test and control groups were determined. Mean OD values of binding in presence of sera
were normalized as %OD compared to OD values of PvRII binding in absence of sera. A
standard curve for PvRII binding to DARC was used to estimate bound PvRII in presence of
sera using the %OD values. The results are expressed as the dilution of sera at which 50%
binding inhibition was observed.
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2.6. ELISPOT
The frequency of peptide-specific T lymphocytes was determined by IFN-γ–specific ELISPOT
as described [23]. Briefly, 96-well nitrocellulose-bottom plates (Multiscreen-HA, Millipore,
Molsheim, France) were coated with 100 μl/well of GZ-4 monoclonal antibody (mAb) at 15
μg/ml (Mabtech Inc., Mariemont, OH) and incubated overnight at 4 °C. The following day,
plates were washed five times in PBS and blocked with RPMI medium containing 10% FCS.
A cytokine cocktail composed of 25 ng/ml each of IL-7 and IL-15 (R&D Systems, Minneapolis,
MN, USA) was added in 100 μl followed by 50 μl of PvRII or negative control recombinant
protein to a final concentration of 10 μg/ml. Cryopreserved PBMC were thawed, washed twice
with RPMI and the cell viability evaluated by Trypan blue exclusion. 2×105 PBMCs were then
added in a volume of 50 μl, bringing the total volume in each well to 200 μl. Incubation was
continued for 24 hours at 37 °C, 5% CO2. After incubation the plates were washed and
incubated with biotinylated mAb 7-B6-1 (Mabtech Inc., Mariemont, OH) followed by
incubation with Streptavidin-HRP. The reaction was developed using 3-amino-9-
ethylcarbazole (AEC) (BD Biosciences Pharmingen, San Jose, CA) and evaluated in an
Immunospot Analyzer (Cellular Technology-Becton Dickinson, San Diego, CA).
Staphylococcal enterotoxin B (SEB) (Sigma Aldrich Corp., St Louis, MO) was used as positive
control for activation. The results are expressed as total number of spot forming cells (SFC)
per 106 splenocytes. Total number for duplicate wells were averaged and normalized to
numbers of IFN-γ spot forming cells per 1×106 PBMC. Average values for negative medium
control wells in the presence of cytokines were subtracted from the average values from
antigen-stimulated wells. To take in to consideration individual variability, recall PvRII-
reactive T cells were calculated by subtracting the spot forming cells obtained with pre-immune
samples.
2.7. Statistical analysis
Antibody levels were log-transformed and multiple comparisons were conducted using
Student’s t-test. To evaluate the correlation between antibody titers and inhibition of binding
of PvRII to DARC-Fc by anti-PvRII rhesus sera, a Spearman rank correlation was used. For
hematology and clinical laboratory values repeated measures of analysis of variance (ANOVA)
were conducted to evaluate overall differences at a particular time point. For the ELISPOT
assays, we tested the significance of the differences between doses using the one-tailed paired
Student’s t-test after subtracting the background spots and using data log transformation. P-
values of 0.05 or less were considered significant.
3. Results
3.1 Safety assessment
Animals were evaluated daily for the presence of clinical abnormalities and general behavior.
They were also examined closely under general anesthesia at days 30, 60, 90, 120, 150 and
180 to identify signs of local reactogenicity. No local abnormalities were identified in the
inoculation sites upon close examination. Hematology and clinical chemistry values
determined at days 0, 30, 60, 90, 120, 150 and 180 remained within the normal range. In some
animals, in both experimental or control groups at different time points, high levels of CPK
were detected randomly without clinical expression of tissue damage. These changes were
considered within a normal range for rhesus macaques housed in social settings where minor
sub-clinical traumas are expected.
3.2 Antibody mediated immune response
We have evaluated six formulations of PvRII using three different clinically accepted
adjuvants. Figure 1 summarizes the kinetics of the anti-rPvRII antibody response determined
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by ELISA. Pre-immune geometric mean antibody titers ranged between 1:200 and 1:3200.
Thirty days after the first immunization all rhesus macaques seroconverted (defined by fourfold
or greater increase over baseline) after receiving PvRII with either formulation with five to
eight-fold increase in titers from the pre-immune values. After a single immunization,
differences were significant only between Montanide and Alhydrogel groups for the 10 μg
protein concentration (P=0.004). This is in contrast with antibody titers evaluated 60 days after
the second immunization where both Montanide and AS02A groups were significantly greater
than Alhydrogel groups (P values: Montanide 50 -Alhydrogel 50 = 0.01; AS02A 50-
Alhydrogel 50 = 0.0009; Montanide 10-Alhydrogel 10 = 0.000277 and AS02A 10-Alhydrogel
10 = 0.015). Differences in antibody titers between animals that received PvRII formulated in
Montanide or AS02A were not significant. These trends were maintained after second boosting
conducted 150 days after the first immunization. Differences in antibody titers obtained with
10 and 50 μg immunization regimes at different time points were only statistically significant
for the PvRII formulated with Alhydrogel (P-values ranged from 0.005 to 0.019). There were
no differences in antibody titers in rhesus macaques that received placebo in comparison to the
pre-immune levels.
3.3. Functional characterization of antibodies elicited by immunization
The ability of the antibodies to block binding of PvRII to DARC was characterized by binding
inhibition assays. Figure 2 summarizes the kinetics of functional antibodies determined at four
different time points expressed as the dilution of sera at which 50% binding inhibition was
observed. Functional antibodies were detected in pools of sera obtained from animals 60 days
after the second immunization with each formulation. When the inhibition of binding profiles
were compared between groups that received 10 or 50 μg with the same adjuvant, differences
were only significant for Alhydrogel (P=0.05). Significant correlations were found between
the antibody titers determined by ELISA and inhibition of binding assays. For statistical
analysis antibody titers determined on days 0, 90, 150 and 180 were used to rank antibody
levels for both protein concentrations and adjuvants used for immunization, and the data were
compared with inhibition of binding using a Spearman rank correlation test. The correlation
between ELISA and inhibition of binding ranked from 0.9048 to 0.9461, all with P values of
<0.05. For overall data the Spearman rank-order correlation between ELISA titers obtained
with adjuvants Alhydrogel, Montanide and AS02A and inhibition of binding coefficient was
0.9097 (P<0.000001).
3.4. T cell recall response
PvRII-specific IFN-γ producing T cells were identified by ELISPOT at different time points.
Broad individual variability was observed in the magnitude of IFN-γ ELISPOT responses.
Normalized results were expressed as IFN-γ Spot Forming Cells (SFC) per million PBMC
after subtracting pre-immune values (Figure 3). For statistical analysis, comparisons between
groups that received 10 μg or 50 μg of PvRII formulated with the same adjuvant were
conducted. The differences observed between 10 μg or 50 μg doses were significant for
Montanide ISA 720 (P=0.0018) and Alhydrogel (P<0.0001).
4. Discussion
The Duffy binding protein is a leading vaccine candidate for protection against P. vivax malaria.
The functional DARC-binding domain is located in region II (PvRII) of P. vivax DBP [9].
PvRII is the prototypical Duffy-binding-like (DBL) domain, which shares structural features
with other receptor-binding domains belonging to the DBL family [8,24,25]. Antibodies
directed against the homologous DBL domains of P. knowlesi DBP and P. falciparum
EBA-175 block red cell invasion by P. knowlesi and P. falciparum respectively providing a
rationale for development of a vaccine for P. vivax malaria based on PvRII [6,10,26,27]. Rhesus
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macaques were used to demonstrate safety and immunogenicity of recombinant PvRII. We
have shown that recombinant PvRII induced comparable levels of antibodies when it is
formulated either with Montanide 720 or AS02A. Titers of antibodies significantly correlate
with their ability to inhibit binding of PvRII to DARC. Antibody levels induced by
immunization with PvRII adsorbed to Alhydrogel were lower than the titers induced by
immunization with PvRII formulated in Montanide ISA 720 and AS02A. Despite these low
antibody titers, sera samples obtained from animals immunized with the Alhydrogel
formulation also had an effect on neutralizing the binding of PvRII to DARC-Fc in vitro.
Functional antibodies that block PvRII-DARC-Fc interaction are likely to inhibit erythrocyte
invasion by P. vivax merozoites. The binding inhibitory activity of such antibodies may serve
as an important in vitro correlate for protection in efficacy trials of a PvRII-based malaria
vaccine [28].
All three PvRII formulations tested in rhesus monkeys were well tolerated. To facilitate the
identification of local reactivity, immunization sites were alternated between right quadriceps
femoris and right and left musculus deltoideus. Systemic reactogenicity was evaluated by
periodic evaluation of hematological and clinical chemistry parameters. Although we found
individual variability, clinical laboratory values remained within normal reference ranges.
These results are comparable to recent reports testing a malaria vaccine candidate in rhesus
macaques using similar adjuvant formulations [29]. The use of rhesus macaques in preclinical
trials of malaria vaccine candidates has recently gained attention [29,30]. Rhesus macaques
are phylogenetically closely related to humans. The broad use of this animal model in
biomedical research has stimulated and facilitated the development of species-specific reagents
[31]. The substantial body size of rhesus macaques, compared with small New World monkeys
[32], also facilitates the routine assessment of clinical laboratory chemistry and hematological
parameters using standard phlebotomy procedures in the course of the trial. Future
investigations using this model can evaluate the efficacy of vaccine candidates based on P.
cynomolgi antigens for proof of principle, with the challenge of different strains of P.
cynomolgi parasites. Animals immunized with P. vivax antigens, as reported here, can also be
challenged with P. cynomolgi parasites as a rigorous test for efficacy, to show and predict the
likelihood of achieving heterologous protection as would be desired in field trials [33].
The prevalence of naturally acquired antibodies to P. vivax DBP increases with age in endemic
areas. This age-dependent pattern of immune recognition also correlates with acquisition of
protection against P. vivax malaria [12,14,34,35]. Acquired anti-DBP antibodies are also
correlated with levels of exposure [36,37]. Relevant for malaria vaccine development, anti-
DBP antibodies are higher in asymptomatic individuals suggesting that the prevalence of P.
vivax DBP antibodies may modify the clinical outcome, reducing the severity of the disease
state [14,36]. The immunological relevance of PvRII has been confirmed by genotypic
characterization of wild isolates, which indicates a decline in the proportion of individuals
infected with multiple PvRII haplotypes with increasing age [38]. We show here that
immunization of rhesus macaques with a refolded PvRII induced functional antibodies with
the potential to inhibit parasite invasion. These results are consistent with the high
immunogenicity and partial protection induced in Aotus monkeys in previously described
experiments [19].
PvRII also contains a cluster of T cell epitopes that are recognized by individuals living in
endemic areas of P. vivax malaria [14,39]. PvRII-specific IFN-γ secreting cells were identified
here at different time points after immunization. Surprisingly, statistically significant
differences were defined in animals immunized with Alhydrogel and Montanide ISA 720
formulations but not with AS02A. Recent clinical trials of malaria vaccine candidates have
defined the complexity of the T cell reactivity and the relevance of using cultured ELISPOT
assays to characterize protective T cells [40]. In contrast with ex vivo ELISPOT assays, as used
Moreno et al. Page 7
Vaccine. Author manuscript; available in PMC 2009 August 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
here, cultured ELISPOT assays involve the in vitro culture of PBMC in the presence of relevant
antigens and IL-2 for several days to identify resting memory cells. This T cell subset persists
for several months after immunization and correlates with protection [41]. We have evaluated
T cell reactivity using ELISPOT after ex vivo stimulation with PvRII. The evidence that PvRII
formulated with different adjuvants induces heterogeneous T cell reactivity in rhesus macaques
requires further characterization and the use of a panel of synthetic peptides for ex vivo
stimulation. It has been described that several assays to test T cell reactivity are required to
have a clear picture of memory cells in clinical trials of malaria vaccine candidates [42].
In conclusion we report that PvRII formulated in the human compatible adjuvants Alhydrogel,
Montanide ISA 720 and AS02A is safe and highly immunogenic in rhesus monkeys. Each
formulation tested elicited high titer binding inhibitory antibodies. These results support further
clinical development of this promising candidate as a vaccine for P. vivax.
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Figure 1.
PvRII formulated with different adjuvants induces high antibody titers in rhesus macaques.
The figure represents the kinetics of the antibody response to PvRII determined by ELISA
using geometric mean antibody titers for individual formulations (± standard deviation). Open
symbols, rhesus macaques immunized with 10 μg PvRII. Closed symbols, rhesus macaques
immunized with 50 μg PvRII. Alhydrogel group (○ ●), Montanide ISA 720 group (▽ ▼) and
AS02A group (□ ■).
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Figure 2.
Binding inhibitory activity of anti-PvRII sera induced by immunization of rhesus macaques
with PvRII formulated with different adjuvants. Sera samples were obtained at different time
points after immunization and tested for inhibition of PvRII binding to DARC-Fc as described
[22]. Functional activity is expressed as sera dilution at which 50% binding inhibition was
observed. Open symbols, rhesus macaques immunized with 10 μg rPvRII. Closed symbols,
rhesus macaques immunized with 50 μg P. vivax DBP RII. Alhydrogel group (○ ●), Montanide
ISA 720 group (▽ ▼) and AS02A group (□ ■).
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Figure 3.
Kinetics of the prevalence of IFN-γ secreting cells determined by ELISPOT in PBMC obtained
from animals immunized with different formulations of rPvRII after ex vivo stimulation with
the recombinant protein. Data are presented for individual animal at different time points and
expressed as IFN-γ spot forming cells per 1×106 PBMC. Average values for medium control
wells in the presence of cytokines were initially subtracted from the average values obtained
from antigen-stimulated wells. To take in consideration individual variability, recall PvRII-
reactive T cells were calculated by subtracting the spot forming cells obtained with pre-immune
samples. Rhesus macaques were immunized with 50 μg P. vivax DBP RII (closed symbols) or
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10 μg P. vivax DBP RII (open symbols) formulated with Alhydrogel (A), Montanide ISA 720
(B) or AS02A (C).
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Table 1
Groups of rhesus macaques immunized with rPvRII using several adjuvant formulations.
Group code rPvRII dosea Adjuvant formulationb
1 50 μg Alhydrogel
2 10 μg Alhydrogel
3 50 μg Montanide ISA 720
4 10 μg Montanide ISA 720
5 50 μg AS02A
6 10 μg AS02A
7 Saline Alhydrogel
8 Saline Montanide ISA 720
9 Saline AS02A
a
Administered intramuscularly in a final volume of 500 μl.
b
Rhesus macaques per experimental groups N=5 and placebo groups N=2.
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